PU139 is a potent pan-histone acetyltransferase (HAT) inhibitor. PU139 blocks the HATs Gcn5, p300/CBP-associated factor (PCAF), CREB (cAMP response element-binding) protein (CBP) and p300 with IC 50 s of 8.39, 9.74, 2.49 and 5.35 μM, respectively In Vitro PU139 inhibits cell growth with GI 50 s of In Vivo PU139 (25 mg/kg; i.p.) synergizes with Doxorubicin used as a prototypic chemotherapeutic drug in growth inhibition . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male NMRI:nu/nu mice (Neuroblastoma xenografts) Dosage: 25 mg/kg Administration: Intraperitoneally (PU139) with Dxorubicin at 8 mg/kg i.v.; Administered on days 14 and 21 as a single dose of each compound or, for combination therapy; both drugs were administered successively within 1 h. Result: Optimum growth inhibition following a single PU139 therapy was moderate, but significant as compared with the untreated group and confirmed the previous findings. Form:Solid IC50& Target:GCN5 8.39 μM (IC 50 ) CREBBP 2.49 μM (IC 50 ) PCAF 9.74 μM (IC 50 ) p300 5.35 μM (IC 50 )
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
PU139
CAS number：158093-65-3 molecular formula：C12H7FN2OS
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | - | ||
| CAS number | 158093-65-3 | molecular formula | C12H7FN2OS |
| molecular weight | 246.26 g/mol | Exact mass | ≥98% |
| PSA | 58.500 Ų | logp | 2.400 |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
